ScienceDaily PharmaceuticalsOriginal article
New mesothelioma drug turns cancer’s own defenses against it
Phase 1positiveexperimental mesothelioma drugPositive
AI Analysis
Summary
Scientists are testing an experimental mesothelioma drug that disables PRX3, a cancer cell defense mechanism, demonstrating disease control in 67% of early trial patients with encouraging survival outcomes.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Controlled disease progression in 67% of patients with encouraging survival results
Importance:5/10
Sentiment:
0.70
mesotheliomaearly-stagemechanism of actionantioxidant defenseclinical trialPRX3 inhibitor
Read the original article
Published by ScienceDaily Pharmaceuticals on September 17, 2026 5:11 AM